An LLC model in biotech brings specific advantages, such as streamlined deal-making, IP ownership, and capital reinvestment ...

Part one of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI ...

In the second article in a series on the leadership benefits of putting employees first, Christine Miller, president and CEO ...

As professionals within the life sciences industry, a new era is upon us, marked by the pursuit of efficiency. In part this has been driven by legislative measures such as the Inflation Reduction Act ...

What does the ICF amendment or revision process look like within a digital platform and is this harder or easier than traditional paper-based approaches? Paper consent revisions involve updating forms ...

Carsten Linnemann, Ph.D., CEO of Neogene Therapeutics and Head of Oncology Cell Therapy Clinical Development, AstraZeneca joins Cell & Gene: The Podcast’s Erin Harris to discuss T-cell receptor (TCR) ...

Stop spending thousands of man-hours on SDTM, ADaM and TFL generation and accelerate the delivery of clinical discoveries to patients. Transform your biostatistics deliveries with ThoughtSphere.

It wouldn't be accurate to say that surgeon-turned-healthcare investment banker and consultant Dr. Ali Pashazadeh traded his scalpels for spreadsheets. In fact, he still wields a scalpel quite ...

Then: In a 2021 “Companies To Watch” article written by Wayne Koberstein, Carisma Therapeutics CEO Steven Kelly spoke about his three-pronged mandate to fund the (then) privately held company, build a ...